Elevation of asymmetric dimethylarginine (ADMA) in patients developing hepatic failure after major hepatectomy

Nijveldt, Robert J.; Teerlink, T.; Siroen, Michiel P. C.; Hoven, B. van der; Prins, H.A.; Sijp, J. R. van der; Cuesta, MiguelA.; Meijer, S.; Leeuwen, P.A. van

doi:10.1016/s0261-5614(03)80172-3

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8 In patients with severely impaired liver function after a major hepatic resection, an increased level of ADMA was observed during the postoperative period. 19 In our work, the ADMA level during reperfusion was the highest in the untreated group subjected to IR, and was significantly higher than in the non-IR group. At 0.5 h of reperfusion, the SDMA level was the highest, which may be an additional reason for the inhibition of the NO production.…”

Section: Groupssupporting

confidence: 46%

The impact of sitagliptin, inhibitor of dipeptidyl peptidase-4 (DPP-4), on the ADMA-DDAH-NO pathway in ischemic and reperfused rat livers

Trocha¹,

Nowak²,

Merwid-Ląd³

et al. 2018

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. A correlation between the level of asymmetric dimethylarginine (ADMA)-the inhibitor of the nitric oxide (NO) synthesis-and the liver function and survival after a liver transplantation has been reported. Objectives. The aim of this study was to evaluate the effect of sitagliptin-the inhibitor of dipeptidyl peptidase-4 (DPP-4)-on the NO-ADMA-dimethylarginine dimethylaminohydrolase (DDAH) pathway in rat livers subjected to ischemia/reperfusion (IR). Material and methods. The rats received sitagliptin (5 mg/kg, per os-p.o.) (groups: Slivers not subjected to IR procedure, and SIR-livers subjected to IR procedure) or a saline solution (groups: C-livers not subjected to IR procedure, and CIR-livers subjected to IR procedure) for 14 days; following this, livers in the SIR and CIR groups were subjected to ischemia (60 min) and reperfusion (24 h). Aminotransferases were measured before the surgery; additionally, the arginine (ARG), ADMA and symmetric dimethylarginine (SDMA) levels were estimated just before ischemia and during reperfusion (at 0.5 h, 4 h and 24 h). After IR, citrulline, the DDAH activity, mRNA for type 1 DDAH (DDAH1), and arginine methyltransferase type 1 (PRMT1) were determined. Results. The increase in the initial level of ARG/ADMA0 (A/A) ratio in group S compared to group C verged on statistical significance. At 0.5 h and 4 h of reperfusion, the highest concentration of ADMA was found in group CIR. At those time points, the ARG level and the A/A ratio were decreased in groups CIR and SIR as compared to groups C and S, respectively. The alanine transaminase (ALT) activity was lower in the sitagliptintreated group than in the non-treated one. The DDAH and citrulline levels were reduced in group CIR as compared to group C, but were greater in group SIR as compared to group S. The PRMT1 mRNA expression was higher in groups CIR and SIR, compared to groups C and S, respectively. Conclusions. The increased A/A ratio suggests a protective effect of sitagliptin on livers not subjected to IR. Changes in the DDAH activity and the PRMT1 mRNA expression also imply the protective activity of sitagliptin during IR.

show abstract

Section: Groupssupporting

confidence: 46%

The impact of sitagliptin, inhibitor of dipeptidyl peptidase-4 (DPP-4), on the ADMA-DDAH-NO pathway in ischemic and reperfused rat livers

Trocha¹,

Nowak²,

Merwid-Ląd³

et al. 2018

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…The liver plays an important role in ADMA clearance, due to the constitutive abundance of DDAH, an enzyme which breaks down ADMA into dimethylamine and citrulline [28]. Therefore, a severely impaired liver function leads to increased plasma levels of ADMA in patients with multiple organ failure [16] or end‐stage liver disease [17], and in patients developing hepatic failure after major hepatectomy [18]. In addition, it has been suggested that in the presence of chronic liver tissue damage and inflammation, ADMA metabolism could be deranged in response to oxidative stress [29], shear stress [30], tumor necrosis factor‐α (TNF‐α) [31] and down‐regulation of DDAH activity by S‐nitrosylation of its active site by NO [32], whose availability from splanchnic sources is increased [33].…”

Section: Discussionmentioning

confidence: 99%

“…This amino acid is primarily metabolized in the liver by dimethylarginine dimethylaminohydrolase (DDAH) [13–15]. Accordingly, impaired liver function may lead to increased plasma levels of ADMA [16–18]. Recently, Lluch and co‐workers found that elevated systemic ADMA levels correlate with the degree of liver failure in patients with alcoholic cirrhosis [19] and in cirrhotic patents with hepatorenal syndrome [20].…”

Section: Introductionmentioning

confidence: 99%

ADMA correlates with portal pressure in patients with compensated cirrhosis

Vizzutti

Romanelli

Arena

et al. 2007

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Their shortcoming could be overcome by the development of a new definition comprising functional biomarkers. At the moment, definitions comprising functional biomarkers like indocyanine green elimination rate (8) or asymmetric dimethylarginine (9) do not exist.…”

Section: Methodsmentioning

confidence: 99%

Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment

Broek

Damink

Dejong

et al. 2008

Liver International

369

257

View full text Add to dashboard Cite

Liver failure is a dreaded and often fatal complication that sometimes follows a partial hepatic resection. This article reviews the definition, incidence, pathogenesis, risk factors, risk assessment, prevention, clinical features and treatment of post‐resectional liver failure (PLF). A systematic, computerized search was performed using key words related to ‘partial hepatic resection’ and ‘liver failure’ to review most relevant literature about PLF published in the last 20 years. The reported incidence of PLF ranges between 0.7 and 9.1%. An inadequate quantity or quality of residual liver mass are key events in its pathogenesis. Major risk factors are the presence of comorbid conditions, pre‐existent liver disease and small remnant liver volume (RLV). It is essential to identify these risk factors during the pre‐operative assessment that includes evaluation of liver volume, anatomy and function. Preventive measures should be applied whenever possible as curative treatment options for PLF are limited. These preventive measures intend to increase RLV and protect remnant liver function. Management principles focus on support of end‐organ and liver function. Further research is needed to elucidate the exact pathogenesis of PLF and to develop and validate adequate treatment options.

show abstract

Elevation of asymmetric dimethylarginine (ADMA) in patients developing hepatic failure after major hepatectomy

Cited by 6 publications

References 0 publications

The impact of sitagliptin, inhibitor of dipeptidyl peptidase-4 (DPP-4), on the ADMA-DDAH-NO pathway in ischemic and reperfused rat livers

The impact of sitagliptin, inhibitor of dipeptidyl peptidase-4 (DPP-4), on the ADMA-DDAH-NO pathway in ischemic and reperfused rat livers

ADMA correlates with portal pressure in patients with compensated cirrhosis

Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment

Contact Info

Product

Resources

About